SOPHiA GENETICS president sells 1,183 shares

SOPHiA GENETICS SA President Ross Muken reported a small open‑market sale of 1,183 Ordinary Shares at a weighted average price of $4.7937 per share.

Rhea-AI Filing Summary

SOPHiA GENETICS SA President Ross Muken reported a small open‑market sale of 1,183 Ordinary Shares at a weighted average price of $4.7937 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan, meaning the transactions were pre-scheduled rather than discretionary. After these sales, Muken directly holds 271,910 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 1,183 shares

Net Sell 1 txn

Insider Muken Ross

Role President

Sold 1,183 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,183	$4.7937	$6K

Holdings After Transaction: Ordinary Shares — 271,910 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) President Ross Muken report in this Form 4?

Ross Muken reported selling 1,183 Ordinary Shares of SOPHiA GENETICS at a weighted average price of $4.7937. The filing notes these shares were sold in the open market to cover tax obligations tied to recently vested restricted stock units.

Why did Ross Muken sell SOPHiA GENETICS (SOPH) shares in this transaction?

The sale was made to satisfy tax obligations related to the vesting of restricted stock units on March 18, 2026. This is described as a tax-related transaction rather than a discretionary sale, helping cover personal tax liabilities triggered by equity compensation.

Were Ross Muken’s SOPHiA GENETICS (SOPH) share sales discretionary or pre-planned?

The sales were executed under a pre-established Rule 10b5-1 trading plan. This means the trades were scheduled in advance under SEC rules and, according to the filing, do not represent discretionary timing decisions by the reporting person.

How many SOPHiA GENETICS (SOPH) shares does Ross Muken hold after this Form 4 transaction?

After selling 1,183 Ordinary Shares, Ross Muken directly holds 271,910 Ordinary Shares of SOPHiA GENETICS. This indicates that the reported sale represents only a small portion of his overall direct equity position in the company.

At what prices were the SOPHiA GENETICS (SOPH) shares sold in Ross Muken’s Form 4?

The Form 4 reports a weighted average sale price of $4.7937 per share. A footnote explains that multiple trades occurred in a price range between $4.69 and $4.87, and detailed trade-level data is available upon written request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/19/2026		S		1,183(1)	D	$4.7937(2)	271,910	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)